Skip to main content

DARPA Supports Brain Treatment

Brain-implant technologies just got a vote of government confidence, as the Defense Advanced Research Projects Agency announces an investment of $70 million over five years.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

WIKIMEDIA, JOHN A BEAL, LSUHSCThe implantation of electrodes to stimulate brain areas malfunctioning in disease is not a new idea. More than 100,000 patients have received such deep-brain stimulation (DBS) treatments for Parkinson’s and other brain disorders, and diverse diseases, including depression and Alzheimer’s, are currently under study for their response to DBS. Last week (October 24), the federal Defense Advanced Research Projects Agency (DARPA) announced its support of continued brain implant research, vowing $70 million over five years to improve DBS techniques and/or develop entirely new technologies.

The initiative, called Systems-Based Neurotechnology and Understanding for the Treatment of Neuropsychological Illnesses, “is a significant development for neuroscience, for bioengineering, and most importantly, for patients,” DBS pioneer Andres Lozano of the University of Toronto told The Scientist in an e-mail. (See Lozano’s feature story on DBS research and therapy, “Tuning the Brain.”)

Specifically, DARPA aims to develop better biomarkers for measuring the effectiveness of DBS, The New York Times reported. “There is no technology that can acquire signals that can tell [scientists] precisely what is going on with the brain,” DARPA program manager Justin Sanchez told NYT. “[DARPA is] trying to change the game on how we approach these kinds of problems.”

One of the agency’s first steps will be to design a brain-monitoring ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Illustrated floating metabolites and molecules

Metabolon Verus™ Kit: Metabolomics Profiling Kit

Metabolon
Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics